Asian Phytoceuticals PCL 2022 IR
The report highlights Asian Phytoceuticals Public Company Limited's (APCO) business operations and sustainability performance for the fiscal year 2022. The company focused on aggressive market strategies for its health products, particularly its rejuvenating immunotherapy formulas MYLIFE100 and MYLIFE100A, and expanded into pet dietary supplements. APCO aligned its operations with the BCG (Bio-Circular-Green) Economy Model, emphasizing natural plant extracts, waste reduction, and environmental preservation. Key achievements include maintaining zero workplace fatalities and initiating a solar rooftop project to reduce greenhouse gas emissions.
Company: Asian Phytoceuticals PCL
Sector: Manufacturing
Country: Thailand
Year: 2022
Type: IR
Pages: 231
Back to company
Asian Phytoceuticals PCL
Annual Registration Statement / Annual Report
The report highlights Asian Phytoceuticals Public Company Limited's (APCO) business operations and sustainability performance for the fiscal year 2022. The company focused on aggressive market strategies for its health products, particularly its rejuvenating immunotherapy formulas MYLIFE100 and MYLIFE100A, and expanded into pet dietary supplements. APCO aligned its operations with the BCG (Bio-Circular-Green) Economy Model, emphasizing natural plant extracts, waste reduction, and environmental preservation. Key achievements include maintaining zero workplace fatalities and initiating a solar rooftop project to reduce greenhouse gas emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Workplace Fatalities
Employees